AMAG Pharmaceuticals Price Target Cut to $30.00 by Analysts at Summer Street (AMAG)
Analysts at Summer Street reduced their target price on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) to $30.00 in a research report issued to clients and investors on Thursday, AmericanBankingNews.com reports. The firm currently has a “buy” rating on the stock. Summer Street’s price target points to a potential upside of 43.75% from the company’s current price.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 0.67% during mid-day trading on Thursday, hitting $21.01. 50,470 shares of the company’s stock traded hands. AMAG Pharmaceuticals has a 1-year low of $15.26 and a 1-year high of $28.42. The stock’s 50-day moving average is $23.35 and its 200-day moving average is $23.50. The company’s market cap is $456.7 million.
A number of other analysts have also recently weighed in on AMAG. Analysts at Jefferies Group upgraded shares of AMAG Pharmaceuticals from an “underperform” rating to a “hold” rating in a research note to investors on Thursday. They now have a $19.00 price target on the stock, up previously from $16.00. Separately, analysts at Ladenburg Thalmann downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday. They noted that the move was a valuation call. Finally, analysts at Zacks downgraded shares of AMAG Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, December 24th. They now have a $29.40 price target on the stock. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. AMAG Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $24.40.
In other AMAG Pharmaceuticals news, Insider Christopher White sold 4,000 shares of the stock in a transaction that occurred on Thursday, January 9th. The shares were sold at an average price of $22.37, for a total value of $89,480.00. Following the completion of the transaction, the insider now directly owns 24,834 shares in the company, valued at approximately $555,537. The transaction was disclosed in a filing with the SEC, which is available at this link.
AMAG Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (NASDAQ:AMAG).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.